TA183 Cervical cancer (recurrent) - topotecan: review decision - December 2012 information
History
Documents created during the development process.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 57 KB)
-
Cervical cancer (recurrent) - topotecan: review proposal - September 2012 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 343 KB)
Cervical cancer (recurrent) - topotecan: final appraisal determination
-
Cervical cancer (recurrent) - topotecan: final appraisal determination information
-
Cervical cancer (recurrent) - topotecan: final appraisal determination
-
Cervical cancer (recurrent) - topotecan: final appraisal determination (PDF 141 KB)
-
Response to consultee and commentator comments on the appraisal consultation document
-
Response to consultee and commentator comments on the appraisal consultation document (PDF 110 KB)
-
Consultee and commentator comments on the ACD
-
Department of Health
-
-
Royal College of Nursing
-
-
GlaxoSmithKline
-
Cervical cancer (recurrent) - topotecan: appraisal consultation
-
Cervical cancer (recurrent) - topotecan: appraisal consultation
-
Cervical cancer (recurrent) - topotecan: appraisal consultations document information
-
Cervical cancer (recurrent) - topotecan: evaluation report
-
Pre-meeting briefing
-
-
Cervical cancer (recurrent) - topotecan: evidence review group report
-
Cervical cancer (recurrent) - topotecan: evidence review group report (PDF 875 KB)
-
NICE clarification letter
-
-
Royal College of Nursing
-
-
Manufacturer submissions
-
Manufacturer response to clarification letter
-
-
GlaxoSmithKline
-
-
Expert written personal statements
-
Oakley
-
-
Pendleton
-
-
Symonds
-
-
Hirschowitz
-
Cervical cancer (recurrent) - topotecan: table of comments on draft scope
-
Cervical cancer (recurrent) - topotecan: table of comments on draft scope
-
Cervical cancer (recurrent) - topotecan: table of comments on draft scope (PDF 80 KB)
Cervical cancer (recurrent) - topotecan: table of comments on draft matrix
-
Cervical cancer (recurrent) - topotecan: table of comments on draft matrix
-
Cervical cancer (recurrent) - topotecan: table of comments on draft matrix (PDF 19 KB)
Cervical cancer (recurrent) - topotecan: matrix
-
Cervical cancer (recurrent) - topotecan: matrix
-
Cervical cancer (recurrent) - topotecan: scope
-
Cervical cancer (recurrent) - topotecan: scope
-